328 W. Claiborne St.
P.O. Box 964
Monroeville, Alabama 36460
(251) 575-4203
     
Alzheimers Disease and other Cognitive Disorders
Resources
Basic Information
Introduction & Causes of Cognitive DisordersDementiaAlzheimer's DiseaseOther Cognitive DisordersDementia Coping Skills & Behavior ManagementTraumatic Brain Injury (TBI)Conclusion and Resources
More InformationLatest News
Alzheimer's Vaccine Shows Promise in MiceKey Strategies When Caring for a Loved One With DementiaAHA: What's the Blood Pressure Connection to Alzheimer's Disease?Could Diabetes Drugs Help Curb Alzheimer's?Hard Arteries Hard on the Aging Brain?Widely Used Antipsychotics May Not Ease Delirium in ICUMap of Mouse Hippocampus Could Be Weapon Against Alzheimer'sHealth Tip: 10 Signs of Alzheimer'sA-Fib Tied to Higher Odds for DementiaAlzheimer's Gene Tied to 'Chemo Brain' in Breast Cancer SurvivorsWhat's the Dollar Cost of Caring for a Loved One With Alzheimer's?AHA: Stiffening of Blood Vessels May Point to Dementia RiskU.S. Alzheimer's Cases to Nearly Triple by 2060Daytime Drowsiness a Sign of Alzheimer's?Exercise May Boost Brain Power in Alzheimer's, Mouse Study SuggestsSeverity of Alzheimer's Can Vary by SeasonHealth Tip: Help Kids Understand Alzheimer'sEyes Could Be Window to Predicting Alzheimer'sDialysis Linked to Dementia in SeniorsWhen Head Injuries Make Life Too Hard, Suicide Risk May RiseMore Alzheimer's Gene Links FoundEye Disease Link to Alzheimer's SeenAlzheimer's Drug Trial Offers New Hope, But Uncertainty, TooGet Dizzy Upon Standing? It Could Be Sign of Dementia RiskVirtual Reality as a Window Into DementiaThe Right Lighting Can Calm Alzheimer's PatientsCould Pot-Linked Drug Help Ease Agitation in Alzheimer's?Many Americans With Dementia Don't Know They Have It: StudyHaving More Kids Tied to Lower Odds of Alzheimer's in WomenWhy Alzheimer's May Be Tougher to Spot in WomenHow Common Is Dementia Among LGBT Seniors?Life Is Short After Dementia Diagnosis, No Matter Your AgeHealth Tip: What's the Difference Between Delirium and Dementia?Obesity Adds to Burden of Traumatic Brain InjuryCould Aspirin Help Keep Alzheimer's Away?Scientists Spot Gene Linking Down Syndrome, Early Alzheimer'sCould Herpes Virus Play a Role in Alzheimer's?Health Tip: Living With Dementia"Markers" of Alzheimers Do Not Doom You to DementiaMaking Life With Dementia More BearableWhen Do You Take Guns From Someone With Dementia?Mild TBI Linked to Increased Dementia Risk in VeteransEven Mild Concussion Tied to Greater Dementia Risk Later'Smart Dresser' Might Help Alzheimer's Patients Clothe ThemselvesMusic May Calm the Agitation of Alzheimer'sRural Childhood, Higher Education Cuts Later Life Dementia RiskControlling High Blood Pressure Could Prevent DementiaAnnual Visits May Not Increase Cognitive Impairment DetectionMild TBI May Increase Risk of Parkinson's DiseaseBrain Injuries Linked With Dementia Risk
Links
Related Topics

Aging & Geriatrics
Memory Problems
Elder Care

Idalopirdine May Not Improve Cognition in Mild Alzheimer's


HealthDay News
Updated: Jan 9th 2018

new article illustration

TUESDAY, Jan. 9, 2018 (HealthDay News) -- The use of idalopirdine does not improve cognition versus placebo over 24 weeks of treatment for patients with mild-to-moderate Alzheimer's disease (AD), according to research published in the Jan. 9 issue of the Journal of the American Medical Association.

Alireza Atri, M.D., Ph.D., from the California Pacific Medical Center in San Francisco, and colleagues conducted three randomized 24-week clinical trials that included 2,525 patients aged 50 years or older with mild-to-moderate AD to examine whether idalopirdine is effective for symptomatic treatment of mild-to-moderate AD.

The researchers found that the mean change in the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog) was 0.37, 0.61, and 0.41 for the 60- and 30-mg idalopirdine groups and the placebo group, respectively (adjusted mean difference versus placebo: 0.05 [95 percent confidence interval (CI), −0.88 to 0.98] and 0.33 [95 percent CI, −0.59 to 1.26], respectively), in study 1. In study 2, the mean change in ADAS-Cog total score was 1.01, 0.53, and 0.56 for the 30- and 10-mg groups, and placebo, respectively (adjusted mean difference versus placebo, 0.63 [95 percent CI, −0.38 to 1.65] for the 30-mg group). The mean change in ADAS-Cog total score in study 3 was 0.38 and 0.82 for the 60-mg and placebo groups, respectively (adjusted mean difference, −0.55 [95 percent CI, −1.45 to 0.36]).

"These findings do not support the use of idalopirdine for the treatment of AD," the authors write.

Several authors disclosed financial ties to medical device and pharmaceutical companies, including H. Lundbeck A/S, which funded the study.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)




328 W. Claiborne St.
P.O. Box 964
Monroeville,
Alabama 36460
Tel: (251)575-4203
Fax:(251)575-9459


powered by centersite dot net